TOVX$0.1805-1.93%
Theriva Biologics, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: NYSE
Mkt Cap:$8.28M
Float & O/S:
Inst Own:
DilutionScan read 28 of Theriva Biologics, Inc.'s SEC filings and found 6 warrant series, 2 convertibles, 1 ATM program, 3 shelf registrations, 2 S-1 registrations and 1 completed offering on file for TOVX. The latest dilution event on file is ATM sales on Jun 30, 2026. Analysis updated Nov 2, 2026.
Signal8 Summary
TOVX
Micro-cap burning cash, 8-month runway, heavy dilution
- Business
- WeakNo revenue, $25.2M net loss, 8.2-month cash runway
- Stock risk
- High$7.8M micro-cap, share count +800% YoY, 41% dilution overhang
Snapshot
Theriva is a clinical-stage biotech with no revenue, a $25.2M net loss in FY 2025, and free cash flow of negative $16.7M.
What's Happening Right Now
- : On Nov 2, 2026, Theriva sold its SYN-004 antibiotic-degrading enzyme portfolio to Biossil Labs for $350,000 upfront plus up to $91M in contingent milestones and royalties, making VCN-01 its lead program.
- : Theriva called a Nov 18, 2026 special meeting to raise authorized shares to 500 million and re-approve warrants covering 16.18 million shares (roughly 35% of shares outstanding) after a prior proxy disclosure error triggered shareholder litigation; three earlier quorum attempts failed.
- : On Sep 30, 2026, Theriva announced peer-reviewed publication in Nature Medicine of VIRAGE Phase 2b results showing improved survival for VCN-01 added to chemotherapy in metastatic pancreatic cancer, with a follow-on VIRAGE2 dosing trial underway.
- : Theriva's Q2 2026 results showed a $3.2M net loss (improved from $13.1M a year earlier), $11.3M in cash as of June 30, 2026, and the first patient dosed in the VIRAGE2 Phase 2a trial.
- : On Aug 6, 2026, Theriva dosed the first patient in the VIRAGE2 Phase 2a trial evaluating more frequent VCN-01 dosing in metastatic pancreatic cancer, with initial data expected by Q3 2027.
- : Sold $2.30M net / 10.20M shares through its at-the-market program, as stated for Jan 1, 2026 to Jun 30, 2026.
- : Sold $2.30M net / 10.20M shares through its at-the-market program, as stated for Jan 1, 2026 to Mar 31, 2026.
- : Sold $6.50M net / 17.29M shares through its at-the-market program, as stated for Oct 1, 2025 to Dec 31, 2025.
